References

Idiopathic inflammatory myopathies

10.1038/s41572-021-00321-x · 2021 · External reference

Idiopathic inflammatory myopathies

10.1016/j.ncl.2014.04.007 · 2014 · External reference

Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy

10.1016/j.jns.2025.123414 · 2025 · External reference

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

10.1073/pnas.94.21.11514 · 1997 · External reference

Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint

10.3389/fimmu.2020.00951 · 2020 · External reference

Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: potential role in cardiovascular diseases

2021 · External reference

Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans

10.1172/jci.insight.131870 · 2020 · External reference

The cytokine growth differentiation factor-15 and skeletal muscle health: portrait of an emerging widely applicable disease biomarker

10.3390/ijms232113180 · 2022 · External reference

The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis

10.1016/j.cyto.2019.154966 · 2020 · External reference

The emerging role of Growth Differentiation Factor 15 as a potential disease biomarker in juvenile dermatomyositis

10.1093/rheumatology/kead654 · 2025 · External reference

The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy

10.1093/rheumatology/keaa721 · 2021 · External reference

Activity prediction modeling based on a combination of growth differentiation factor 15 and serum biomarker levels in dermatomyositis and polymyositis

10.1016/j.arcmed.2024.103058 · 2024 · External reference

119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands

10.1016/j.nmd.2004.02.006 · 2004 · External reference

188th ENMC international workshop: inclusion body myositis, 2–4 December 2011, Naarden, the Netherlands

10.1016/j.nmd.2013.08.007 · 2013 · External reference

224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Zandvoort, the Netherlands, 14–16 October 2016

10.1016/j.nmd.2017.09.016 · 2018 · External reference

Revised equations for estimated GFR from serum creatinine in Japan

10.1053/j.ajkd.2008.12.034 · 2009 · External reference

GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients

10.1002/jcsm.13513 · 2024 · External reference

Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders

10.1002/ana.24506 · 2015 · External reference

Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

10.1016/j.mito.2019.10.005 · 2020 · External reference

Retrospective study shows that serum levels of chemokine CXCL10 and cytokine GDF15 support a diagnosis of sporadic inclusion body myositis and immune-mediated necrotizing myopathy

10.3390/brainsci13101369 · 2023 · External reference

Growth differentiation factor-15 as an emerging biomarker for identifying myositis

10.1080/1744666x.2022.2021879 · 2022 · External reference

Growth differentiation factor-15 and risk of CKD progression

10.1681/asn.2016080919 · 2017 · External reference

Growth differentiation factor-15 and incident chronic kidney disease: a population-based cohort study

10.1186/s12882-021-02558-w · 2021 · External reference

Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure

10.1016/j.jacc.2007.04.091 · 2007 · External reference

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure trial

10.1161/circulationaha.109.928846 · 2010 · External reference